AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Jamison Private Wealth Management Inc.

Jamison Private Wealth Management Inc. boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 28,334 shares of the company’s stock after purchasing an additional 1,141 shares during the period. Jamison Private Wealth Management Inc.’s holdings in AstraZeneca were worth $1,856,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Stratos Wealth Advisors LLC raised its stake in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares during the period. Crumly & Associates Inc. raised its position in AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares during the period. Diversify Wealth Management LLC lifted its holdings in AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after purchasing an additional 153 shares in the last quarter. Veery Capital LLC grew its position in shares of AstraZeneca by 4.7% in the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after purchasing an additional 157 shares during the period. Finally, Harbour Investments Inc. increased its stake in shares of AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after purchasing an additional 160 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on AZN. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Up 0.7 %

Shares of NASDAQ:AZN opened at $69.06 on Friday. The business has a 50-day moving average price of $66.44 and a 200 day moving average price of $74.18. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $214.16 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm earned $0.87 EPS. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. Sell-side analysts expect that AstraZeneca PLC will post 4.12 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.